Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yin Xing Tong Zhi tablets (YXTZTs) are a traditional Chinese medicine (TCM) formulation consisting of extracts derived from *Ginkgo biloba*, with ginkgo ketone ester (comprising ginkgo flavonol glycosides and terpene lactones) as the active ingredient. Manufactured by SPH XingLing Technology Pharmaceutical, the drug is primarily used for its neuroprotective, anti-inflammatory, and antioxidant properties. It is approved in China for vascular cognitive impairment and is being investigated for chemotherapy-related cognitive impairment (CRCI) in breast cancer patients. The tablets work by reducing pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α, and mitigating oxidative stress to preserve cognitive function and protect against neuroinflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yin Xing Tong Zhi tablets.